ATE42545T1 - Imidazolide, verfahren zu deren herstellung und deren anwendung als zwischenprodukte in der synthese von cytotoxischen nebenprodukten. - Google Patents
Imidazolide, verfahren zu deren herstellung und deren anwendung als zwischenprodukte in der synthese von cytotoxischen nebenprodukten.Info
- Publication number
- ATE42545T1 ATE42545T1 AT85401200T AT85401200T ATE42545T1 AT E42545 T1 ATE42545 T1 AT E42545T1 AT 85401200 T AT85401200 T AT 85401200T AT 85401200 T AT85401200 T AT 85401200T AT E42545 T1 ATE42545 T1 AT E42545T1
- Authority
- AT
- Austria
- Prior art keywords
- imidazolides
- synthesis
- processes
- production
- intermediate products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8409703A FR2566271B1 (fr) | 1984-06-20 | 1984-06-20 | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
FR8409704A FR2566403B1 (fr) | 1984-06-20 | 1984-06-20 | Imidazolides, procede d'obtention et application a titre d'intermediaires de synthese de conjugues cytotoxiques |
EP85401200A EP0169112B1 (de) | 1984-06-20 | 1985-06-18 | Imidazolide, Verfahren zu deren Herstellung und deren Anwendung als Zwischenprodukte in der Synthese von cytotoxischen Nebenprodukten |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE42545T1 true ATE42545T1 (de) | 1989-05-15 |
Family
ID=26224019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT85401200T ATE42545T1 (de) | 1984-06-20 | 1985-06-18 | Imidazolide, verfahren zu deren herstellung und deren anwendung als zwischenprodukte in der synthese von cytotoxischen nebenprodukten. |
Country Status (6)
Country | Link |
---|---|
US (1) | US4670563A (de) |
EP (1) | EP0169112B1 (de) |
JP (1) | JPH0625143B2 (de) |
AT (1) | ATE42545T1 (de) |
CA (1) | CA1283661C (de) |
DE (1) | DE3569732D1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
IN165717B (de) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4839375A (en) * | 1987-07-28 | 1989-06-13 | Merrell Dow Pharmaceuticals Inc. | (Aryl or heteroaromatic methyl)-2,2'-bi-1H-imidazoles and their use as anti-hypertensive agents |
US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
EP0044167A3 (de) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Durch einen Antikörper gerichtetes zytotoxisches Mittel |
FR2516794B1 (fr) * | 1981-11-20 | 1985-10-25 | Sanofi Sa | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
-
1985
- 1985-06-11 US US06/743,659 patent/US4670563A/en not_active Expired - Fee Related
- 1985-06-11 CA CA000483680A patent/CA1283661C/en not_active Expired - Fee Related
- 1985-06-18 AT AT85401200T patent/ATE42545T1/de not_active IP Right Cessation
- 1985-06-18 EP EP85401200A patent/EP0169112B1/de not_active Expired
- 1985-06-18 DE DE8585401200T patent/DE3569732D1/de not_active Expired
- 1985-06-20 JP JP60135216A patent/JPH0625143B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPS6112683A (ja) | 1986-01-21 |
US4670563A (en) | 1987-06-02 |
DE3569732D1 (en) | 1989-06-01 |
CA1283661C (en) | 1991-04-30 |
EP0169112B1 (de) | 1989-04-26 |
JPH0625143B2 (ja) | 1994-04-06 |
EP0169112A1 (de) | 1986-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3789682D1 (de) | Verfahren zur Herstellung von 1-Desoxynojirimycin und dessen N-Derivaten. | |
ATE104271T1 (de) | 2-(2-hydroxy-3phenoxypropylamino)ethylphenoxyacetamide, verfahren und zwischenprodukte zu deren herstellung. | |
DE69023934D1 (de) | Substanz PF 1022, Verfahren zu ihrer Herstellung und diese Substanz enthaltende anthelmintische Zusammensetzung. | |
IL73893A0 (en) | 11-beta arylestradienes,their production,and pharmaceutical preparations containing same | |
ATE129503T1 (de) | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien. | |
ATE62683T1 (de) | Labdanderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel. | |
ATE10368T1 (de) | Uracilderivate, verfahren zu ihrer herstellung und eine diese enthaltende pharmazeutische zubereitung. | |
ATE42545T1 (de) | Imidazolide, verfahren zu deren herstellung und deren anwendung als zwischenprodukte in der synthese von cytotoxischen nebenprodukten. | |
GR71207B (de) | ||
HUT38340A (en) | Process for producing benzyl-phtalazinone derivatives and pharmaceutical compositions containing them | |
CA1273957C (de) | ||
ATE66209T1 (de) | Dihydropyridinamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln. | |
ATE35812T1 (de) | Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen. | |
ATE172976T1 (de) | 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
DE68917660D1 (de) | Harnstoffhaltige 2,4,6-Triaminopyrimidin-3-oxid-Derivate, deren Herstellung und deren Verwendung für Kosmetika und Hautpharmazie. | |
DK0457090T3 (da) | Fremgangsmåde til fremstilling af 3-amino-2-(het)-aroyl-acrylsyrederivater | |
ATE14126T1 (de) | Verfahren zur herstellung von 2-acyl1,3,4,6,7,11b-2h-hexahydro-4-pyrazino(2,1a)isochinolinonen und zwischenprodukte. | |
DE59308091D1 (de) | Alkenylbernsteinsäurederivate als Metallbearbeitungshilfsmittel | |
DE3575139D1 (de) | Phenylnaphthyridine, verfahren zu deren herstellung, diese enthaltende arzneimittel, insbesondere antigeschwuer. | |
ATE2423T1 (de) | 1-acyloxyphenyl-1,2-diphenylalken-derivate, verfahren zu deren herstellung und eine diese derivate enthaltende pharmazeutische zusammensetzung. | |
ATE2794T1 (de) | 1-n-alkylsisomicin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
HUT49122A (en) | Process for producing pharmaceutical compositions containing pyridyl-ethanol-amine as active component and the active component | |
ATE131155T1 (de) | Verfahren zur herstellung von zwischenprodukten und zur synthese von n-(2-hydroxyethyl)-2- hydroxymethyl-3,4,5-trihydroxypiperidine. | |
ATE110061T1 (de) | Optisch aktive 2,3-dihydrobenzoxazinderivate und verfahren zu deren herstellung. | |
DE68906049D1 (de) | Benzocyclohexan- und benzocycloheptan-derivate und deren salze, verfahren und zwischenprodukte zu deren herstellung, deren verwendung als heilmittel und diese enthaltende zusammensetzungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |